Aadi bioscience to join russell 2000® and russell 3000® indexes

Los angeles, june 23, 2022 (globe newswire) -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today announced it will join both the u.s. small cap russell 2000® index and broad-market russell 3000® index at the conclusion of the 2022 russell indexes annual reconstitution, effective immediately after the u.s. market opens on june 24, 2022 according to a preliminary list of additions posted by ftse russell on june 3, 2022.
AADI Ratings Summary
AADI Quant Ranking